CompanyScope

United Therapeutics Corporation income statement & cash flow

Ticker UTHR · SEC CIK 1082554 · Latest fiscal year ended Dec 31, 2025

In the fiscal year ended Dec 31, 2025, United Therapeutics Corporation reported net income of $1.33B on revenue of $3.18B. Operating cash flow was $1.56B and capital expenditures were $520.50M, leaving $1.04B of free cash flow (operating cash flow minus capital expenditures).

−$500M$0$500M$1B$2BDec 2016: $713.70MDec 2017: $417.90MDec 2018: $589.20MDec 2019: −$104.50MDec 2020: $514.80MDec 2021: $475.80MDec 2022: $727.30MDec 2023: $984.80MDec 2024: $1.20BDec 2025: $1.33BDec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
United Therapeutics Corporation net income by fiscal year, USD. Hover a bar for the exact figure.

Income statement and cash flow summary

Fiscal year endedDec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue (USD)$1.60B$1.73B$1.63B$1.45B$1.48B$1.69B$1.94B$2.33B$2.88B$3.18B
Gross profit (USD)———$1.33B$1.38B$1.56B$1.78B$2.07B$2.57B$2.80B
Operating income (USD)$1.06B$814.90M$805.40M−$187.60M$593.60M$555.90M$979.70M$1.18B$1.38B$1.49B
Net income (USD)$713.70M$417.90M$589.20M−$104.50M$514.80M$475.80M$727.30M$984.80M$1.20B$1.33B
Diluted EPS (USD per share)$15.25$9.31$13.39−$2.39$11.54$10.06$15.00$19.81$24.64$27.86
Operating cash flow (USD)$643.60M$474.20M$778.40M−$206.60M$755.70M$598.20M$802.50M$978.00M$1.33B$1.56B
Capital expenditures (USD)$38.00M$86.30M$184.40M$83.70M$59.30M$120.80M$138.80M$230.40M$246.50M$520.50M
Reported in10-K 201910-K 202010-K 202010-K 202010-K 202310-K 202410-K 202510-K 202610-K 202610-K 2026

Columns are fiscal years, labeled by the month the year ended; scroll sideways on small screens. — means the company did not report the figure under the XBRL concepts we track.

Margins

Each figure divided by revenue for the same fiscal year.

Fiscal year endedGross marginOperating marginNet margin
Dec 202587.9%46.9%41.9%
Dec 202489.2%47.9%41.5%
Dec 202388.9%50.9%42.3%
Dec 202292.2%50.6%37.6%
Dec 202192.7%33.0%28.2%
−$500M$0$500M$1B$2B$2BDec 2016: $643.60MDec 2017: $474.20MDec 2018: $778.40MDec 2019: −$206.60MDec 2020: $755.70MDec 2021: $598.20MDec 2022: $802.50MDec 2023: $978.00MDec 2024: $1.33BDec 2025: $1.56BDec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
United Therapeutics Corporation operating cash flow by fiscal year, USD. Hover a bar for the exact figure.

Source: SEC EDGAR XBRL company facts for CIK 1082554 (raw data). Most recent filing in this dataset: 10-Q filed Aug 5, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.